Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maël Heiblig

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Expert Opinion on Pharmacotherapy|February 7, 2020
An evaluation of glasdegib for the treatment of acute myelogenous leukemiaXavier Thomas, Maël Heiblig
Cancers|December 16, 2020
Acute Promyelocytic LeukemiaXavier Thomas, Maël Heiblig
Rheumatology (Oxford, England)|July 31, 2023
From vacuoles to VEXASMaël Heiblig, Pierre Sujobert
Expert Opinion on Drug Discovery|August 23, 2016
The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatmentXavier Thomas, Maël Heiblig
International Journal of Hematologic Oncology|October 11, 2018
Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemiaXavier Thomas, Maël Heiblig
Best Practice & Research. Clinical Rheumatology|August 31, 2023
VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of viewMaël Heiblig, Bhavisha Patel, Yvan Jamilloux
Expert Review of Hematology|April 21, 2020
Emerging pharmacotherapies for elderly acute myeloid leukemia patientsXavier Thomas, Mohamed Elhamri, Maël Heiblig
Current Opinion in Hematology|February 2, 2023
VEXAS: where do we stand 2 years later?Pierre Sujobert, Maël Heiblig, Yvan Jamilloux
Expert Opinion on Emerging Drugs|June 24, 2022
Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trialsXavier Thomas, Mohamed Elhamri, Alexandre Deloire, et al.
World Journal of Stem Cells|September 2, 2015
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsMaël Heiblig, Mohamed Elhamri, Mauricette Michallet, et al.
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Expert Opinion on Pharmacotherapy|February 7, 2020
An evaluation of glasdegib for the treatment of acute myelogenous leukemiaXavier Thomas, Maël Heiblig
Cancers|December 16, 2020
Acute Promyelocytic LeukemiaXavier Thomas, Maël Heiblig
Rheumatology (Oxford, England)|July 31, 2023
From vacuoles to VEXASMaël Heiblig, Pierre Sujobert
Expert Opinion on Drug Discovery|August 23, 2016
The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatmentXavier Thomas, Maël Heiblig
International Journal of Hematologic Oncology|October 11, 2018
Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemiaXavier Thomas, Maël Heiblig
Best Practice & Research. Clinical Rheumatology|August 31, 2023
VEXAS syndrome, a new kid on the block of auto-inflammatory diseases: A hematologist's point of viewMaël Heiblig, Bhavisha Patel, Yvan Jamilloux
Expert Review of Hematology|April 21, 2020
Emerging pharmacotherapies for elderly acute myeloid leukemia patientsXavier Thomas, Mohamed Elhamri, Maël Heiblig
Current Opinion in Hematology|February 2, 2023
VEXAS: where do we stand 2 years later?Pierre Sujobert, Maël Heiblig, Yvan Jamilloux
Expert Opinion on Emerging Drugs|June 24, 2022
Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trialsXavier Thomas, Mohamed Elhamri, Alexandre Deloire, et al.
World Journal of Stem Cells|September 2, 2015
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptorsMaël Heiblig, Mohamed Elhamri, Mauricette Michallet, et al.
Pageof 8